MURRAY HILL, N.J., April 20, 2016 /PRNewswire/ -- Linde LLC and IMA Life North America are inviting pharmaceutical manufacturers involved in freeze drying of delicate biotech and non-biotech derived products, such as injectable solutions, proteins, peptides, and vaccines, to participate in a Webinar to discuss ground-breaking results of a study that has tested proprietary controlled nucleation technology on a production scale.
The Webinar, "Lessons Learned for Successful Induced Nucleation at Production Scale: Review and Scale-up Case-Study Using VERISEQ® Nucleation," will take place on April 22, at 4:30 pm (GMT+1), 10:30 am (EDT), 7:30 am (PDT). Interested practitioners can find the invitation at: http://www.adverclick.it/mail/17730/1704389/Live+webinar:+Lessons+Learned+for+Successful+Induced+Nucleation.html
"This study is the first demonstration of the success in applying controlled nucleation to one of the largest in the industry -- 56 square-meter freeze dryer operating at a load of 195,960 vials," said Eugene Wexler, Linde's senior project manager, Chemicals & Environment, Applications Technology Americas. "Until now, there has been no commercially feasible way of achieving uniform ice nucleation on a production scale."
The Webinar will highlight the advantages of Linde's proprietary VERISEQ® Nucleation technology, which controls formation of ice crystals using a sterile cryogenic ice fog resulting in enhanced lyophilization (freeze drying) cycles and improved product characteristics.
Linde LLC introduced its VERISEQ Nucleation technology at the 2012 World Exhibition Congress on Chemical Engineering, Environmental Protection and Biotechnology. Since then, Linde has been collaborating with leading freeze drying equipment manufacturer IMA Life North America to commercialize this technology.
Linde North America is a member of The Linde Group. In the 2015 financial year, The Linde Group generated revenue of USD19.7 bn (EUR 17.944 bn), making it one of the leading gases and engineering companies in the world, with approximately 65,000 employees working in more than 100 countries worldwide. The strategy of The Linde Group is geared towards long-term profitable growth and focuses on the expansion of its international business with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development.
For more information, see The Linde Group online at www.linde.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmaceutical-manufacturers-invited-to-webinar-on-ground-breaking-production-scale-controlled-nucleation-freeze-drying-300254574.html
SOURCE Linde North America, Inc.